
|Articles|May 1, 2008
Genentech changes ranibizumab programs
Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis)-including Lucentis Access Solutions and the Genentech Access to Care Foundation-in an effort to improve enrollment timing and broaden eligibility requirements.
Advertisement
South San Francisco, CA-Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis)-including Lucentis Access Solutions and the Genentech Access to Care Foundation-in an effort to improve enrollment timing and broaden eligibility requirements.
The changes include:
For more information, physicians and patients may contact 866/724-9394 or
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
The Residency Report: Cardiovascular risk scores as a window into ocular disease
3
FDA guidance to help accelerate cell and gene therapies
4
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
5





















